Search

A recent study conducted by researchers at "Lucian Blaga" University of Sibiu focused on drug-drug interactions of selective serotonin reuptake inhibitors (SSRIs) in treating depression. The study aimed to evaluate real-world data from the EudraVigilance database on six SSRIs authorized in Europe. Findings showed that while SSRIs are effective in treating depression, they can lead to adverse effects and interactions, emphasizing the importance of monitoring and awareness among healthcare professionals. The study concluded that drug-drug interactions, although a small percentage of reported adverse reactions, can have severe outcomes and should be addressed collaboratively by physicians and pharmacists. [Extracted from the article]

A study conducted at South Ural State University in Chelyabinsk, Russia, focused on unraveling the serotonergic mechanism of stress-related anxiety and the potential co-treatment with resveratrol and selective serotonin reuptake inhibitors (SSRIs). The research found that chronic stress exposure led to increased serotonin levels and upregulation of serotonin transporter (SERT) and 5-HT3A receptor gene expression. While SSRIs did not effectively reduce anxiety or serotonin levels, resveratrol showed promise in reducing anxiety and restoring serotonin, especially when used in combination with sertraline. The study suggests potential therapeutic strategies for anxiety disorders by targeting these mechanisms. [Extracted from the article]

Researchers have submitted a patent application for a method of treating depressed patients with poor cognition using a benzylpiperazine-aminopyridine agent. The application highlights the challenges in selecting effective antidepressant medications based on trial-and-error methods and the need for improved treatments for depression. Despite promising early studies, a Phase 2 clinical trial did not demonstrate the efficacy of NSI-189, leading to the discontinuation of its development. The patent application aims to address the need for antidepressants with different mechanisms of action for treating depression. [Extracted from the article]

A patent application titled "Hallucinogen-Fatty Acid Combination" was published online by Mindset Pharma Inc., detailing the synergistic effects of combining hallucinogens and fatty acids in animal models for hallucinogenic activity. The application discusses the potential therapeutic benefits of this combination for treating mental health disorders and neurological conditions by targeting serotonin receptors. The patent application includes pharmaceutical compositions, kits, and methods for administering hallucinogens and fatty acids to improve efficacy in treating various diseases and conditions. The application highlights the safety profile of psychedelic drugs and their potential as neurotherapeutics for treatment-resistant psychiatric and neurological diseases. [Extracted from the article]

A patent application has been submitted for a method of treating posttraumatic stress disorder (PTSD) by administering an oral dosage form of Compound A for at least 8 weeks. PTSD is a common psychiatric condition resulting from exposure to traumatic events, with women being twice as likely as men to develop PTSD. The treatment aims to address the urgent need for advancements in pharmacotherapy for PTSD, focusing on maintaining specific plasma concentrations of Compound A and endocannabinoid anandamide. [Extracted from the article]

A recent study from Ajou University School of Medicine in South Korea examined the safety of combining methylphenidate and selective serotonin reuptake inhibitors (SSRIs) in adults with attention-deficit/hyperactivity disorder (ADHD) and comorbid depression. The study found that there was no significant increase in adverse event risk associated with this combination therapy, and it was even linked to a lower risk of headache. Additionally, sensitivity analyses showed that the risk of hypertension and hyperlipidemia was lower in the fluoxetine group compared to the escitalopram group. [Extracted from the article]

A study conducted at Akdeniz University in Turkey examined the frequency and risk factors of akathisia, an extrapyramidal side effect of antidepressants, in patients receiving selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors (SSRI/SNRI). The research found that akathisia was observed in 25% of patients, with smokers and younger patients being more affected. The study concluded that akathisia may reduce treatment compliance and quality of life in patients with mood disorders, especially in certain demographic groups. Further investigations are needed to confirm the risk factors and consequences of SSRI/SNRI-induced akathisia. [Extracted from the article]

Johnson & Johnson is jettisoning several programs, with three of those culls in neuroscience. [ABSTRACT FROM AUTHOR]

This document is a patent application for a method of treating major depressive disorder in patients with cognitive impairment or poor cognition. The inventors propose administering a specific medication, NSI-189, to these patients, despite previous reports of its ineffectiveness. The method involves objectively assessing cognitive impairment or poor cognition in patients and administering the medication alongside other antidepressant medications. The patent application also includes methods for treating late-life depression and provides specific dosage recommendations for the medication. [Extracted from the article]

A recent study conducted at Tel Aviv University in Israel explored changes in neural function associated with two different treatments for social anxiety disorder (SAD): selective serotonin reuptake inhibitors (SSRIs) and attention bias modification (ABM) therapy. The study involved 81 patients with SAD who were assigned to either SSRI treatment, ABM therapy, or a waitlist control group. The results showed that both the SSRI and ABM groups experienced greater clinical improvement compared to the waitlist group. The study also found specific neural activation changes in response to each treatment, suggesting that patients who do not fully benefit from one treatment may benefit from the other or a combination of both. [Extracted from the article]

A report from Aarhus University Hospital Psychiatry in Denmark explores the sociodemographic and clinical factors associated with treatment outcomes in older adults who initiated selective serotonin reuptake inhibitors (SSRIs) for depression. The study analyzed data from Danish registries and followed 65,741 individuals with a mean age of 78.23 years for one year after their SSRI prescription. The study found that certain factors, such as being female, residing in rural areas, and having certain psychiatric or somatic diagnoses, were associated with fewer unfavorable clinical outcomes. Conversely, being single or separated and using nervous system drugs were linked to a higher risk of unfavorable outcomes. The research emphasizes the importance of considering patient characteristics in clinical decisions for depression treatment. [Extracted from the article]

A recent study conducted at the Second Hospital of Shandong University examined the effects of selective serotonin reuptake inhibitors (SSRIs) on patients with Alzheimer's disease (AD). The study analyzed the cognitive functions, mental improvements, and adverse effects of five representative drugs (citalopram, s-citalopram, quetiapine, olanzapine, and sertraline). The results showed that these antidepressants had significant advantages in AD treatment compared to a placebo, although there were no notable changes in the Mini-Mental State Examination (MMSE) scores. The study suggests that further research on the application of SSRI-related antidepressants in AD treatment is necessary. [Extracted from the article]

A scoping review conducted by researchers at Georgetown University School of Medicine explored the use of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) in reducing symptoms of Meniere's disease (MD), including vertigo, tinnitus, and hearing loss. The review included four published studies involving 147 patients with MD. The findings suggest that SSRIs and TCAs may reduce the frequency of tinnitus and vertigo, but there is a need for larger-scale studies to evaluate their effectiveness. The researchers emphasize the importance of objective data in future studies. [Extracted from the article]

A study conducted at Virginia Commonwealth University explores the relationship between fetal behavior and gestational exposure to serotonin reuptake inhibitors (SRIs) in mothers with depression. The researchers examined three groups of mother-infant pairs: mothers with untreated depression, mothers treated with SRIs for depression, and non-depressed and untreated mothers. The study found that lower levels of platelet serotonin (5-HT) were observed in the group of mothers treated with SRIs, and these lower levels were associated with more immature fetal movement quality. The researchers suggest that platelet 5-HT levels may serve as a valuable indicator of the effects of gestational SRI exposure on fetal and perinatal neurobehavior. [Extracted from the article]

This patent application discusses the use of racemic ketamine as a potential treatment for suicidality, suicidal ideation, and major depressive disorder. The inventors acknowledge the limitations of current depression treatments and propose intranasal administration of racemic ketamine as a more rapid and effective option. The method may be used in combination with other therapies and shows potential for individuals with post-traumatic stress disorder as well. The application provides specific details about dosages, timing of administration, and potential side effects. [Extracted from the article]

A report from Pontifical University Javeriana in Bogota, Colombia discusses the use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression, anxiety, and obsessive-compulsive disorder in children and adolescents. While SSRIs are generally safe and well-tolerated, they can cause activation syndrome, which can negatively impact treatment adherence and response. Activation syndrome is characterized by symptoms such as impulsiveness, restlessness, increased activity, insomnia, irritability, disinhibition, and agitation. The syndrome is poorly defined and understood, making it difficult to recognize and evaluate. Further research is needed to determine its prevalence, risk factors, and relationship with suicidal tendencies. Strict vigilance is recommended when using SSRIs in this population. [Extracted from the article]

A clinical trial, NCT06545474, is currently underway to compare the effects of repetitive transcranial magnetic stimulation (rTMS) and selective serotonin reuptake inhibitor (SSRI) medication as early treatments for depression. The trial involves 106 patients with non-treatment resistant major depression who will be randomly assigned to receive either 4 weeks of bilateral theta burst stimulation (TBS) or 4 weeks of SSRI medication in Stage I. The allocation to Stage II will depend on therapy response, with patients either continuing with maintenance treatment or switching to the other treatment arm. The primary outcome will be therapy response measured with the Montgomery-Asberg Depression Rating Scale (MADRS) after 4 weeks at the end of Stage I. This document provides information about a clinical study that is not yet recruiting participants. The study aims to investigate the effectiveness of different treatments for moderate to severe major depressive disorder (MDD). The two treatment options being studied are SSRI medication (specifically escitalopram) and bilateral theta burst stimulation (TBS). The study will involve 106 participants and is expected to be completed by December 31, 2026. The eligibility criteria for participants include age between 18 and 65 years, a diagnosis of MDD, and no previous antidepressant treatment. The study is being conducted by the University Hospital Tuebingen in collaboration with the German Center for Mental Health. [Extracted from the article]

A report from researchers at the University of Florence discusses the potential withdrawal effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). The researchers found that current diagnostic methods, such as the DSM, do not adequately account for withdrawal symptoms when identifying mental disorders. They suggest that additional clinimetric tools, like the Diagnostic Clinical Interview for Drug Withdrawal, should be used alongside the DSM to accurately detect withdrawal syndromes caused by SSRI/SNRI discontinuation or decrease. The study emphasizes the need for a more comprehensive approach to diagnosing mental disorders in the context of medication withdrawal. [Extracted from the article]

The article discusses a study on identifying local field potential biomarkers for obsessive-compulsive disorder (OCD) treatment with deep brain stimulation, conducted by West China Hospital, and published in the journal Clinical Trials Week on August 19, 2024. Topics include the use of deep brain stimulation in OCD patients, the application of machine learning to neural signals, and the development of personalized treatment approaches based on biomarkers.

A recent study conducted in Ras al Khaymah, United Arab Emirates, examined the prescription patterns of antidepressants and the prevalence of polypharmacy in a psychiatry outpatient setting. The study found that there has been a shift towards newer antidepressants with better tolerability and safety. The majority of patients received monotherapy, with selective serotonin reuptake inhibitors being the most commonly prescribed drugs. However, a significant number of patients also received concomitant administration of antidepressants or psychotropic drugs, highlighting the need for careful monitoring. [Extracted from the article]

A recent study conducted by the University of Gothenburg in Sweden compared the effectiveness of three selective serotonin reuptake inhibitors (SSRIs) - sertraline, citalopram, and escitalopram - in the treatment of depression. The study aimed to address the issue of confounding by indication, which occurs when the choice of medication is influenced by the severity of the condition. The researchers analyzed data from Danish registers and found that there was no significant difference in the effectiveness of the three SSRIs in treating depression. However, they noted that considering potential confounding factors, such as patent-related prescription patterns, is crucial in pharmacoepidemiological studies. [Extracted from the article]

A recent systematic review and meta-analysis conducted by researchers at Alborz University of Medical Science in Karaj, Iran, compared the effectiveness of saffron versus selective serotonin reuptake inhibitors (SSRIs) in treating depression and anxiety. The analysis included randomized controlled trials (RCTs) and found that saffron showed similar effectiveness to SSRIs in reducing depressive and anxiety symptoms. Additionally, participants receiving saffron experienced fewer adverse events compared to those in the SSRI group. The researchers suggest that saffron could be a potential alternative to SSRIs for treating depression and anxiety, but further research is needed to validate these findings. [Extracted from the article]

A patent application has been filed for a new method of treating major depressive disorder (MDD) in patients with moderate or severe anhedonia, a core symptom of depression. The method involves administering an effective amount of a compound called aticaprant, or a pharmaceutically acceptable salt thereof, to patients who have had an inadequate response to other antidepressant therapies. The patent application suggests that aticaprant may be effective in modulating the negative affective state associated with stress response and improving symptoms of depression. The inventors also propose the use of aticaprant as an adjunctive treatment with other antidepressants. [Extracted from the article]

A systematic review conducted by researchers at the University of Ottawa explores the impact of depression treatment on outcomes after total joint arthroplasty (TJA) procedures. The review analyzed ten studies involving 33,501 patients with diagnosed depression who underwent TJA. The findings suggest that interventions targeted at patients with depression may improve short-term pain and functional outcomes, and there may be a connection between the use of selective serotonin reuptake inhibitors (SSRIs) and implant survival. The researchers recommend that surgeons consider depression treatment as a means to enhance outcomes in this patient population. [Extracted from the article]

A patent has been issued for compositions and methods for the treatment of depression. The inventors propose the use of aticaprant, or a pharmaceutically acceptable salt thereof, to treat major depressive disorder in patients with moderate or severe anhedonia. This treatment may be used in conjunction with other antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). The patent is assigned to Janssen Pharmaceuticals Inc. and provides potential therapeutic options for patients with depression and anhedonia. [Extracted from the article]

A recent systematic review conducted by researchers at Universita Cattolica del Sacro Cuore in Rome, Italy, evaluated the efficacy of selective serotonin reuptake inhibitors (SSRIs) in reducing symptoms of depression in patients on chronic hemodialysis. The review included seven studies with a total of 433 patients. The results showed that SSRIs may be effective in reducing symptoms of depression in this population, and the administration of SSRIs at the dosage used in the studies appeared to be safe. However, further randomized, controlled studies are needed to determine if SSRIs can be routinely used in clinical practice for patients on chronic hemodialysis. [Extracted from the article]

A recent study conducted by the University of Saskatchewan in Canada has found that selective serotonin reuptake inhibitors (SSRIs) can reduce interpersonal sensitivity in patients with acute major depressive disorder. The study analyzed data from three clinical trials involving 1,709 patients who were treated with fluoxetine and paroxetine. Both medications were found to significantly reduce interpersonal sensitivity compared to a placebo. The researchers suggest that future clinical trials should consider assessing interpersonal sensitivity more routinely. This study provides valuable insights into the potential benefits of SSRIs in treating interpersonal sensitivity in depressed patients. [Extracted from the article]

A recent study conducted by the University of Florida has found that the use of selective serotonin reuptake inhibitors (SSRIs) in individuals with Parkinson's disease (PD) is associated with greater apathy. Apathy is a common motivational disorder in PD that is often misdiagnosed as depression. The study examined the relationship between apathy and SSRI use in 400 individuals with PD and found that SSRIs were the only antidepressants significantly associated with higher apathy scores. The findings suggest that considering apathy is important when prescribing antidepressants to individuals with PD, and further research is needed to explore alternative treatments for apathy in this population. [Extracted from the article]

Researchers from Carol Davila University of Medicine and Pharmacy in Bucharest, Romania have published a report on depression, exploring the relationship between mental activity and computer software. They suggest that mental activity is dependent on the brain, which functions similarly to a computer's hard drive. The researchers propose a pharmacological approach using selective serotonin reuptake inhibitors (SSRIs) to reset mental activity without interrupting or altering existing mental data. This study provides a synthesis of previous articles and offers a potential avenue for further research in the field of mental health. [Extracted from the article]

A recent preprint abstract discusses the computational modeling of specific serotonin reuptake inhibitor (SSRI) inhibition on the TREK-2 channel, a mechanosensitive potassium channel. The study shows that fluoxetine and escitalopram, two commonly used SSRIs, share the same binding pocket on the TREK-2 channel. Fluoxetine inhibits the channel by disrupting channel gating at the selectivity filter, while escitalopram acts as a traditional pore blocker. Both SSRIs prevent a down-to-up transition when pressure is applied to the system. This research provides insight into the mechanism of TREK-2 channel inhibition by lipid-like antidepressants and may contribute to future rational drug design. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted by the University of Minnesota highlights the importance of detecting and treating peripartum depression, which is a common disorder during pregnancy. The study emphasizes the need for pregnant individuals to be screened for depression using validated tools and to be offered psychotherapy and medication as treatment options. Risk factors for peripartum depression include a history of depression, physical or sexual abuse, unplanned or unwanted pregnancy, and traumatic birth. Cognitive behavior therapy and interpersonal psychotherapy are recommended as the main treatments, with selective serotonin reuptake inhibitors considered for moderate to severe cases. However, fluoxetine and paroxetine should be avoided during pregnancy due to an increased risk of birth defects. [Extracted from the article]

A report from Monash University in Clayton, Australia discusses new findings on the association between depression and hypertensive disorders of pregnancy (HDP). The study examined 815 pregnant women and found that those with unmedicated depression and those taking serotonin and noradrenaline reuptake inhibitors (SNRIs) had a significantly higher risk of developing HDP compared to controls. However, the use of selective serotonin reuptake inhibitors (SSRIs) did not confer any increased risk. The research suggests that pregnant women with depression or taking SNRIs should be closely monitored for the development of HDP. [Extracted from the article]

A recent study conducted by researchers at University College London (UCL) aimed to develop a prediction model for post-treatment symptom severity in adults with generalized anxiety disorder (GAD). The study used data from adults receiving treatment for GAD and compared thirteen machine learning algorithms to identify the best-performing model. The researchers found that a Bayesian Additive Regression Trees model outperformed other models and accurately predicted post-treatment symptom severity using only pre-treatment data. This model has the potential to inform treatment decision-making and provide valuable information to clinicians and patients receiving treatment for GAD. [Extracted from the article]

A study conducted at a children's hospital in Tampa, Florida explored the association between the combination of selective serotonin reuptake inhibitors (SSRIs) and stimulants and the risk of suicide among children and youth. The study found that patients prescribed both SSRIs and stimulants had a higher prevalence of suicidal thoughts and behaviors compared to those prescribed stimulants only. However, when adjusting for other factors such as age, sex, and diagnoses of anxiety and depression, the association between the medication regimen and suicidal thoughts and behaviors was attenuated. The study suggests that other factors, particularly depression, may contribute to the association between SSRI treatment and suicide risk. Larger prospective studies are needed to further investigate this relationship and guide clinical decision-making. [Extracted from the article]

A study published in Drug Week examined the metabolic effects of three treatments for major depressive disorder: escitalopram, duloxetine, and Cognitive Behavioral Therapy (CBT). The study analyzed serum samples from 163 treatment-naive outpatients using targeted liquid chromatography-electrochemistry. The results showed that escitalopram and duloxetine led to reductions in serum serotonin levels and increases in tryptophan-derived indoles, while CBT did not. The study also found that different metabolites correlated with symptom improvement in the different treatment arms, suggesting potentially different mechanisms of response to antidepressant medications and CBT. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A patent application for a sustained-release injectable pharmaceutical dosage form containing escitalopram base has been made available online. The inventors highlight the prevalence of depression worldwide and the significant impact it can have on individuals' lives, including the potential for suicide. They note that while oral administration of antidepressants, particularly serotonin reuptake inhibitors, has been the most common treatment for depression, there is a need for alternative treatment options that could improve patient compliance and adherence. The patent application describes the dosage form and its potential use in treating psychiatric conditions such as Major Depressive Disorder, Generalized Anxiety Disorder, and Social Anxiety Disorder. [Extracted from the article]

This document provides information about a clinical trial, NCT06328140, that is being conducted to compare the effects of Lurasidone and selective serotonin reuptake inhibitor (SSRI) treatment on sleep quality, cognitive performance, and computerized cognitive training (CCT) in patients with major depression. The trial aims to assess the impact of these interventions on cognitive function and daytime sleepiness. The trial is not yet recruiting participants and is expected to be completed by April 2026. It is being conducted in the United States by the George West Mental Health Foundation in collaboration with Sumitomo Pharmaceuticals America. [Extracted from the article]

A recent study conducted by Mayo Clinic in Rochester, Minnesota explored the prevalence of antidepressant prescriptions and investigated sex differences and age-sex interactions in adults enrolled in the RIGHT study. The study found that antidepressant prescription prevalence was higher in women compared to men, and there was a significant age-sex interaction for selective serotonin reuptake inhibitors (SSRIs). The results suggest that age should be considered as a mediator when studying sex differences in mental illness and their treatment. However, there are limitations to the study, such as the lack of information on treatment duration or adherence and the non-representativeness of the cohort. [Extracted from the article]

A recent report from the Hospital for Sick Children in Toronto, Canada discusses the use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety in a child with aromatic L-amino acid decarboxylase (AADC) deficiency post gene therapy. AADC deficiency is an ultrarare genetic disorder that causes motor impairment and developmental delays. While treatment guidelines typically advise against using SSRIs in AADC deficiency due to potential side effects, this case study found that a cautious trial of sertraline significantly reduced anxiety without adverse effects. The report highlights the need to reevaluate existing evidence and treatment guidelines in the era of genetic therapies. [Extracted from the article]

A recent study published in the Mental Health Weekly Digest explores the use of PET imaging to examine the serotonin 1A receptor in individuals with major depressive disorder (MDD). The study utilized novel hierarchical multivariate analysis techniques to overcome discrepancies in previous studies. The results showed higher serotonin 1A autoreceptor binding potential in the raphe nuclei of not-recently-medicated MDD patients compared to both healthy volunteers and antidepressant-exposed MDD patients. These findings align with the biological role of the serotonin 1A autoreceptor in regulating serotonin activity and provide a resolution to previous conflicting results. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted at the Second Affiliated Hospital of Xi'an Jiaotong University examined the safety profiles and adverse events associated with selective serotonin reuptake inhibitors (SSRIs), which are commonly prescribed for depression. The researchers analyzed data from the Food and Drug Administration Adverse Event Reporting System (FAERS) and identified 427,655 adverse event reports for six different SSRIs. The study found that all SSRIs had strong signals related to congenital, psychiatric, and nervous disorders. However, the researchers concluded that further validation is needed to fully understand the adverse events attributed to SSRIs. This study highlights the importance of utilizing data-mining methods to gain additional insights into the safety of SSRIs. [Extracted from the article]

A report from Aarhus University Hospital Psychiatry in Denmark examines the comparative effectiveness of selective serotonin reuptake inhibitors (SSRIs) for comorbid depression in older adults with chronic somatic diseases. The study includes 43,061 individuals aged 65 years with a first prescription for depression with sertraline, escitalopram, or citalopram. The findings suggest that citalopram use is associated with lower risks in several analyses, while escitalopram use may lead to poorer outcomes compared to sertraline. The researchers emphasize the need for clinical studies in this patient population to further investigate these differences. [Extracted from the article]

A study conducted at ESIC Medical College in Haryana, India, explored the treatment of depressive episodes in young patients with hidden bipolarity who were exposed to selective serotonin reuptake inhibitors (SSRIs). The study found that patients who were positive for bipolarity tended to have higher scores on depression and suicidal ideation scales compared to patients who were negative for bipolarity. Additionally, the study suggested that close clinical monitoring and regular follow-up during antidepressant initiation are recommended to reduce the risk of suicidality. The study acknowledges limitations such as a small sample size and short follow-up duration. [Extracted from the article]

A recent study conducted by researchers at the University of Pennsylvania explored predictors and moderators of clinical worsening in patients with obsessive-compulsive disorder (OCD) who discontinued their serotonin reuptake inhibitor (SRI) medication after successful exposure and response prevention therapy. The study included 101 participants, with 35 of them experiencing clinical worsening and being removed from the trial. The researchers found that individuals with more past diagnoses were more likely to experience clinical worsening. Additionally, several factors were identified as moderators, including shorter half-life SRI medication, being female, higher levels of maladaptive metacognitions, fewer sleep problems at baseline, and more years of education. The study provides insights into factors that may predict clinical worsening in OCD patients discontinuing SRI medication after successful therapy. [Extracted from the article]

A recent study conducted at Favaloro University in Buenos Aires, Argentina, explored the relationship between melancholic features of Major Depressive Disorder (MDD) and the effectiveness of treatment with Selective Serotonin Reuptake Inhibitors (SSRIs). The study analyzed data from a large randomized controlled trial and found that melancholic MDD patients had lower probabilities of remission at 4 months when receiving treatment with citalopram, a type of SSRI. The researchers concluded that subtyping depressive episodes based on melancholic features could contribute to personalized treatment for depression. It is important to note that the study's findings may not be applicable to other antidepressant medications or to patients with psychotic MDD. [Extracted from the article]

This document provides information about a clinical trial, NCT06216535, investigating the use of the antidepressant escitalopram in asthma patients with frequent exacerbations. Previous studies have shown that escitalopram can improve asthma control and reduce exacerbations in depressed individuals with asthma. The trial will involve 105 participants with moderate to severe persistent asthma and will last for 24 weeks. The primary outcome measure will be the number of asthma exacerbations requiring systemic corticosteroids. The study will also explore the psychological and biological mechanisms underlying the effect of escitalopram on asthma. The trial is overseen by Sherwood Brown, MD, PhD, from the University of Texas Southwestern Medical Center and is expected to be completed by June 1, 2029. [Extracted from the article]

A new report discusses research findings on depression and its connection to persistent inflammation in people with HIV, despite antiretroviral therapy. The study evaluated the impact of selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs) on inflammation and neurodegeneration in people with HIV. The results showed that SSRIs were associated with reduced neurodegeneration, immune activation, and oxidative stress, suggesting a potential role for SSRIs as adjunctive therapy in people with HIV. The research was conducted by the University of California San Diego and received financial support from the National Institutes of Health. [Extracted from the article]

A recent study conducted by researchers at Guangdong Pharmaceutical University in China has identified dapoxetine, a selective serotonin reuptake inhibitor (SSRI) commonly used to treat premature ejaculation, as a potential inhibitor of Zika virus (ZIKV) infection. The researchers screened a library of FDA-approved drugs and found that dapoxetine exhibited anti-ZIKV effects by inhibiting the activity of the virus's RNA-dependent RNA polymerase. The study suggests that dapoxetine could be a potential candidate for clinical therapeutic intervention against ZIKV infection. Further research is needed to explore its efficacy in vivo. [Extracted from the article]

A recent study conducted by the National Aeronautics and Space Administration (NASA) explores the use of selective serotonin reuptake inhibitors (SSRIs) and alternative therapies for the treatment of mental health conditions during deep space missions. The study highlights the potential risks and side effects associated with SSRIs, such as reduced bone mineral density and impaired hemostatic function. It emphasizes the need to explore nonpharmacological treatments to mitigate these risks. The research suggests that alternative therapies may show promise for long-duration missions and calls for further investigation in this area. [Extracted from the article]

A recent study conducted by researchers at the University of Florida College of Pharmacy examined the risk of fractures in patients who were concurrently using calcium channel blockers (CCBs) and selective serotonin reuptake inhibitors (SSRIs) for hypertension and depression. The study found that concomitant use of CCBs and SSRIs was associated with a higher risk of fractures compared to CCB-only users. However, there was no significant difference in fracture risk between concomitant users of CCBs and CYP3A4-inhibiting SSRIs versus non-CYP3A4 inhibiting SSRIs. The study suggests that short-term concomitant use of CCBs and SSRIs may increase fracture risk. [Extracted from the article]